Each ml contains Carboplatin USP 10 mg, Water for Injection I.P. q.s. Contains no antimicrobial preservative
Without a Prescription
Carboplatin is prescribed in the initial treatment of advanced ovarian cancer and as secondary treatment of advanced ovarian cancer.
NOTE: Aluminium reacts with carboplatin causing precipitate formation and loss of potency, therefore, needles or intravenous sets containing aluminium parts that may come in contact with the drug must not be used for the preparation or administration of Carboplatin.
Single Agent Therapy
Carboplatin as a single agent has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 /m 2 I.V. on day 1 every 4 weeks (alternatively see formula dosing).
In general, however, single intermittent courses of Carboplatin should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.
Combination therapy with cyclophosphamide:
In the chemotherapy of advanced ovarian cancer, an effective combination for previously untreated patients consists of Carboplatin-300 /m 2 I.V. on day 1 every 4 weeks for six cycles (alternatively see formula dosing).
Cyclophosphamide - 600 /m 2 I.V. on day 1 every 4 weeks for six cycles.
Intermittent courses of Carboplatin in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.
Dose Adjustment Recommendations
Pretreatment platelet count and performance status are important prognostic factors for severity of myelosuppression in previously treated patients.
The suggested dose adjustments for single agent or combination therapy shown in the table below are modified from controlled trials in previously treated and untreated patients with ovarian carcinoma.
Blood counts were done weekly, and the recommendations are based on the lowest post-treatment platelet or neutrophil value.
1. Carboplatin is contraindicated in patients with a history of severe allergic reactions to Cisplatin or other platinum containing compounds.
2. Carboplatin should not be employed in patients with severe bone marrow depression or significant bleeding.
- Single dose vials of 15 ml and 45 ml.